Virtu Financial LLC bought a new position in shares of Immune Design Corp (NASDAQ:IMDZ) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 29,460 shares of the biotechnology company’s stock, valued at approximately $172,000. Virtu Financial LLC owned 0.06% of Immune Design as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently bought and sold shares of the business. Marshall Wace LLP purchased a new stake in shares of Immune Design in the 3rd quarter worth $36,000. Personal Capital Advisors Corp increased its stake in Immune Design by 56.3% in the 4th quarter. Personal Capital Advisors Corp now owns 37,500 shares of the biotechnology company’s stock worth $49,000 after buying an additional 13,500 shares in the last quarter. GSA Capital Partners LLP increased its stake in Immune Design by 97.7% in the 4th quarter. GSA Capital Partners LLP now owns 41,068 shares of the biotechnology company’s stock worth $53,000 after buying an additional 20,300 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Immune Design in the 4th quarter worth $58,000. Finally, Rhumbline Advisers increased its stake in Immune Design by 41.0% in the 4th quarter. Rhumbline Advisers now owns 46,946 shares of the biotechnology company’s stock worth $61,000 after buying an additional 13,660 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.
Shares of NASDAQ:IMDZ remained flat at $$5.85 during trading on Wednesday. Immune Design Corp has a 1 year low of $1.10 and a 1 year high of $5.85. The company has a market capitalization of $282.96 million, a price-to-earnings ratio of -3.34 and a beta of 3.48.
IMDZ has been the subject of a number of research analyst reports. HC Wainwright lowered Immune Design from a “buy” rating to a “neutral” rating in a research report on Thursday, February 21st. Zacks Investment Research upgraded Immune Design from a “sell” rating to a “hold” rating in a research report on Monday, March 18th. Finally, Royal Bank of Canada lowered Immune Design from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $9.00 to $6.00 in a research report on Friday, February 22nd. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company. Immune Design currently has an average rating of “Hold” and a consensus price target of $5.17.
TRADEMARK VIOLATION NOTICE: This report was posted by Sundance Herald and is owned by of Sundance Herald. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://sundanceherald.com/2019/05/22/virtu-financial-llc-takes-172000-position-in-immune-design-corp-imdz.html.
Immune Design Profile
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Read More: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.